


(Z)2S,4R-Sacubitril

| | | | |
|--------------------|-------------------------------------------------|-------|---------|
| Cat. No.: | HY-Z0075 | | |
| Molecular Formula: | C ₂₄ H ₂₇ NO ₅ | | |
| Molecular Weight: | 409.47 | | |
| Target: | Drug Metabolite | | |
| Pathway: | Metabolic Enzyme/Protease | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 2 years |
| | | -20°C | 1 year |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (244.22 mM; Need ultrasonic)

| Concentration | Mass | | | |
|---------------|-----------|------------|------------|--|
| | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4422 mL | 12.2109 mL | 24.4218 mL | |
| 5 mM | 0.4884 mL | 2.4422 mL | 4.8844 mL | |
| 10 mM | 0.2442 mL | 1.2211 mL | 2.4422 mL | |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

(Z)2S,4R-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and Drug Administration for use in combination with valsartan for the treatment of patients with heart failure.

REFERENCES

[1]. Shi J, et al. Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation. Drug Metab Dispos. 2016 Apr;44(4):554-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA